Zealand Pharma's Petrelintide Phase 2 Data at ADA 2026: Amylin Analog Challenges GLP-1 Dominance with Differentiated Tolerability
At the American Diabetes Association (ADA) 2026 Scientific Sessions in New Orleans (June 5–8, 2026), Zealand Pharma presented highly anticipated global Phase 2 data from its ZUPREME-1 trial of petrelintide, an investigational long-acting amylin analog. The results establish petrelintide as a potent and highly tolerable non-GLP-1 alternative for chronic weight management, positioning it to advance to Phase 3 trials in the second half of 2026.
Amylin is a pancreatic beta-cell hormone that regulates appetite and satiety by targeting different neurological pathways than GLP-1. By avoiding GLP-1 receptor pathways, petrelintide achieves clinically meaningful weight loss while dramatically reducing the severe gastrointestinal (GI) side effects that frequently plague GLP-1 users.
Key Clinical Findings from ZUPREME-1
- Efficacy: In the 485-patient, randomized, double-blind, placebo-controlled trial, diabetes-free participants with obesity or overweight achieved mean body weight reductions of 8.7% to 10.7% at week 42 across all five investigated doses, compared to a mere 1.7% reduction for placebo.
- Dramatically Improved Tolerability: The rate of diarrhea in the pooled petrelintide group was identical to placebo (7.4% vs. 7.4%), while the rate of vomiting was actually lower than placebo (3.0% vs. 6.2%). Nausea was higher with petrelintide than placebo (19.6% vs. 6.2%), but 77% of these events were classified as mild.
- Ultra-Low Discontinuation Rates: Only 1.5% of petrelintide participants discontinued treatment due to GI adverse events (compared to 0% for placebo), and overall adverse event discontinuations were just 4.5% (vs. 4.9% for placebo). These rates are significantly lower than the typical 5–10% discontinuation rates observed in pivotal GLP-1 clinical trials.
- Cardiovascular Benefits & Pulse Rate Safety: Petrelintide was associated with key cardiovascular and metabolic improvements at week 42, including reductions in waist circumference (-7.9 to -10.8 cm vs. -4.3 cm) and triglycerides (-12% to -21% vs. -9%). Crucially, unlike GLP-1 receptor agonists—which typically increase heart rate—amylin analogs like petrelintide were shown to actually reduce pulse rate.
Verbatim Quotes and Context
- Dr. W. Timothy Garvey, lead investigator from the University of Alabama at Birmingham, commenting on the clinical relevance of a 10% weight loss profile:
"A lot of patients don't require 25%, 30% weight loss -- they don't feel good, they have higher risk of malnutrition and changes in body composition that may be deleterious in some patients."
- Dr. Garvey contrasting petrelintide's tolerability with GLP-1s:
"These are half the rates that we observe within GLP-1 trials. Why should our patients have to feel sick to their stomach for the privilege of having their disease treated?"
- Dr. Garvey on the primary care appeal:
"These amylin therapies have the properties where this could emerge as a first-line treatment in obesity -- not in all patients but in most patients -- because it's well tolerated, and it's attractive for primary care, who's going to end up treating most of this disease."
Market and Investor Implications
- A Primary Care Blockbuster Candidate: While triple-agonist molecules like Eli Lilly's retatrutide push weight loss limits to 30%, their high rate of severe GI side effects and treatment dropouts present a barrier. Petrelintide offers an "easy-to-tolerate" option that is highly suited for primary care physicians who manage the bulk of obesity cases but lack the resources to handle intensive patient titration and side-effect management.
- Combination Potential: Because amylin and GLP-1 target distinct biological pathways, they are highly complementary. Zealand Pharma and Roche are already preparing to evaluate a combination of petrelintide with Roche's dual GLP-1/GIP agonist enicepatide (RG6640, formerly CT-388) in Phase 2 trials, aiming to combine high-potency weight loss with superior tolerability.